Company profile
Solventum Corporation
NYSE: SOLV · Healthcare · Medical - Instruments & Supplies
#45 of 1,418 Healthcare companies by revenue44th-percentile growth
EA Score
65BFH 84DQ 38GM 62SS 67
v0.1 · 65/100 weight · provisional
↑ growth stability, workforce scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$8.3B
Rev growth YoY (TTM)
-0.6%
Net income (FY)
$1.6B
Employees
20,000
as of 2026-08-05
Market cap
$15.2B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$8.3B$8.3B2025
Net income$1.6B$1.6B2025
Operating income$2.2B$2.2B2025
Total assets$14.3B$14.3B2025
Liabilities$9.2B$9.2B2025
Equity$5.0B$5.0B2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
UNITED STATES56%
Non-US44%
The read
What is Solventum Corporation’s revenue?
Solventum Corporation booked $8.3B in FY2025 revenue, growing 0.9% year over year — about the middle of the pack among Healthcare companies we track, at a 18.7% net margin.
Peers · Healthcare
Intuitive Surgical, Inc.90ABiogen Inc.85AZoetis Inc.82B+Zimmer Biomet Holdings, Inc.80B+Agilent Technologies, Inc.85AAvantor, Inc.68BNeighbors
Ramsey →Key facts
CEOBryan C. Hanson
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersMaplewood, MN
ExchangeNYSE: SOLV
Employees20,000
IPO date2024-04-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.